• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FCRI Index

FCRI Index

January 11, 2021

CWW Unveils FCRI, a Stock Index of 10 Publicly Traded Clinical Trials Companies

This week, CenterWatch Weekly (CWW) is unveiling the First Clinical Research Index (FCRI), a stock index of 10 publicly traded clinical trials companies. Once a month, CWW will publish the prior month’s calculation of the FCRI to show how the industry’s top stocks are faring compared to three other widely followed indices: the Standard & Poor’s (S&P) 500 index, the S&P Pharmaceutical Index and the S&P Biopharmaceutical Index. For more information about the index, read on.

Notes on Indices

First Clinical Research Index (FCRI). Calculated as the mean average percentage change from baseline, dividends excluded, adjusted for stock splits. In other words, the indices are not weighted for stock price or market capitalization. Prices are in local currencies. Index components may change from time to time based on new listings, mergers and other factors. Components include 10 publicly traded clinical research stocks: CMIC (2309:JP), EPS (4282:JP), Hangzhou Tigermed Consulting (300347:CH), ICON (ICLR:US), IQVIA Holdings (IQV:US), Medpace Holdings (MEDP:US), PRA Health Sciences (PRAH:US) and Syneos Health (SYNH:US).

S&P 500 Index (SPX). Capitalization-weighted representative sample of 500 mostly large-capitalization companies in leading industries of the U.S. economy.

S&P 500 Pharmaceutical Index (S5PHARX). Capitalization-weighted S&P 500 companies engaged in research, development or production of pharmaceuticals.

S&P 500 Biotechnology Index (S5BIOTX). Capitalization-weighted S&P 500 companies primarily involved in development, manufacturing or marketing of products based on advanced biotechnology research.

Stock and index prices are available at http://www.bloomberg.com/ and http://bigcharts.marketwatch.com/industry/bigcharts-com/industrychart.asp.

Upcoming Events

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing